natgillin/translations-raw huggingface dataset:
"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, 
"heteroaril" označava bilo koju mono- ili bi-cikličku skupinu sastavljenu od 5 do 10 članova prstena, koji imaju najmanje jednu aromatsku polovicu te sadrže od 1 do 3 heteroatoma odabrana od kisika, sumpora i dušika,
Compound of formula (I) according to claim 1, wherein R6 represents an optionally substituted linear or branched (C1-C6)alkoxy group or a -O-alkyl(C1-C6)-R10 group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R6 predstavlja po izboru supstituiranu ravnu ili razgrananu (C1-C6)alkoksi skupinu ili skupinu -O-alkil(C1-C6)-R10.
Compound of formula (I) according to claim 1, wherein R9 and R9' independently of one another represent a linear or branched (C1-C6)alkyl group, or the substituents of the pair (R9, R9') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C1-C6)alkyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R9 i R9’ neovisno jedan o drugome predstavljaju ravnu ili razgrananu (C1-C6)alkilnu skupinu ili supstituente para (R9, R9’) koji zajedno s dušikovim atomom koji ih nosi tvore ne-aromatski prsten sastavljen od 5 do 7 članova prstena, koji osim atoma dušika dodatno može sadržavati od 1 do 3 heteroatoma odabrana od kisika, sumpora i dušika, kada je poznato da predmetni dušik može biti supstituiran sa skupinom koja predstavlja atom vodika, ravnu ili razgrananu (C1-C6)alkilnu skupinu.
Compound of formula (I) according to claim 1, wherein Cy2 represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group or a cyclopropyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da Cy2 predstavlja fenilnu skupinu, skupinu piridinila, skupinu pirazolila, skupinu morfolinila, skupinu furanila ili ciklopropilnu skupinu.
Compound of formula (I) according to claim 1, wherein R10 represents -Cy1-Cy2 in which Cy1 represents a pyrimidinyl group and Cy2 represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group, or a cyclopropyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da R10 predstavlja -Cy1-Cy2gdje Cy1 predstavlja skupinu pirimidinila i Cy2 predstavlja fenilnu skupinu, skupinu piridinila, skupinu pirazolila, skupinu morfolinila, skupinu furanila ili ciklopropilnu skupinu.
Compound of formula (VIA), a particular case of compound of formula (VI) according to claim 22: wherein: 
Spoj formule (VIA), poseban slučaj spoja formule (VI) u skladu s patentnim zahtjevom 22: naznačen time, da:
Compound of formula (VIIA), a particular case of compound of formula (VII) according to claim 22: wherein: 
Spoj formule (VIIA), poseban slučaj spoja formule (VII) u skladu s patentnim zahtjevom 22: naznačen time, da:
Compound of formula (VIB), a particular case of compound of formula (VI) according to claim 22: wherein: 
Spoj formule (VIB), poseban slučaj spoja formule (VI) u skladu s patentnim zahtjevom 22:
Compound of formula (VIIB), a particular case of compound of formula (VII) according to claim 22: wherein: 
Spoj formule (VIIB), poseban slučaj spoja formule (VII) u skladu s patentnim zahtjevom 22: naznačen time, da:
Pharmaceutical composition according to claim 32 for use in the treatment of cancers and of auto-immune and immune system diseases. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 32, naznačen time, da se koristi za liječenje karcinoma i bolesti autoimunog i imunološkog sustava.
Pharmaceutical composition according to claim 33 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 33, naznačen time, da se koristi u liječenju karcinoma mokraćnog mjehura, mozga, dojke i maternice, kroničnih limfoidnih leukemija, karcinoma debelog crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutnih mijeloidnih leukemija, limfoma, melanoma, zloćudnih hemopatija, mijeloma, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, gušterače i karcinoma pluća malih stanica.
Use of a pharmaceutical composition according to claim 31 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 31, naznačena time, što se koristi u proizvodnji lijekova za uporabu u liječenju karcinoma i bolesti autoimunog i imunološkog sustava.
Use of a pharmaceutical composition according to claim 31 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer. 
Uporaba farmaceutskog pripravka u skladu s patentnim zahtjevom 31, naznačena time, što se koristi u proizvodnji lijekova za uporabu u liječenju karcinoma mokraćnog mjehura, mozga, dojke i maternice, kroničnih limfnih leukemija, karcinoma debelog crijeva, jednjaka i jetre, limfoblastičnih leukemija, akutnih mijeloidnih leukemija, limfoma, melanoma, zloćudne hemopatije, mijeloma, karcinoma jajnika, karcinoma pluća ne-malih stanica, karcinoma prostate, gušterače i karcinoma pluća malih stanica.
An antibody having the ability of binding to CLDN18.2 for use in a method of treating a cancer disease of a human patient by avoiding grade 4 and grade 5 adverse events of the patient, wherein the antibody is administered at a dose of at least 300 mg/m2 so as to provide a serum level of at least 40 µg/ml, wherein the antibody comprises an antibody heavy chain comprising the amino acid sequence represented by SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence represented by SEQ ID NO: 39, and wherein the antibody heavy chain comprises the amino acid sequence represented by SEQ ID NO: 17 and the antibody light chain comprises the amino acid sequence represented by SEQ ID NO: 24, wherein the antibody is administered at a dose of up to 1000mg/m2. 
Antitijelo koje se ima sposobnost vezanja na CLDN18.2 za uporabu u postupku liječenja bolesti raka ljudskog pacijenta izbjegavanjem neželjenih događaja pacijenta stupnja 4 i 5, pri čemu se antitijelo daje u dozi od najmanje 300 mg / m2 tako da se osigura nivo seruma od najmanje 40 µg / ml, pri čemu antitijelo sadrži teški lanac antitijela koji sadrži sekvencu aminokiselina predstavljenu SEQ ID NO: 32 i laki lanac antitijela koji sadrži sekvencu aminokiselina predstavljen SEQ ID NO: 39, i pri čemu teški lanac antitijela sadrži aminokiselinsku sekvencu predstavljenu SEQ ID NO: 17, a laki lanac antitijela sadrži sekvencu aminokiselina predstavljenu sa SEQ ID NO: 24, pri čemu se antitijelo daje na doza do 1000mg/m2.
The antibody for use of claim 1 or 2, wherein the serum level is provided for at least 7 days. 
Antitijelo za uporabu prema zahtjevu 1 ili 2, naznačeno time, da je razina u serumu osigurana najmanje 7 dana.
The antibody for use of claim 5, wherein the antibody is administered in at least 3 doses. 
Antitijelo za uporabu u skladu s patentnim zahtjevom 5, naznačeno time da se antitijelo daje u najmanje 3 doze.
The antibody for use of claims 5 or 6, wherein the doses of the antibody are administered in time intervals of at least 7 days. 
Antitijelo za uporabu prema patentnom zahtjevu 5 ili 6, naznačeno time da se doze antitijela daju u vremenskim intervalima od najmanje 7 dana.
The antibody for use of any one of claims 1 to 11, wherein the antibody mediates cell killing by one or more of complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent cellular cytotoxicity (ADCC) mediated lysis, induction of apoptosis and inhibition of proliferation. 
Antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 11, naznačeno time da protutijelo posreduje ubijanje stanica jednim ili više liza posredovane citotoksičnošću (CDC), staničnom citotoksičnošću posredovanom antitijelom (ADCC), liziranom, indukcijom apoptoze i inhibicijom proliferacije.
The antibody for use of any one of claims 1 to 14, wherein the patient had prior therapy with at least one drug selected from the group consisting of pyrimidine analogs, platinum compounds, epirubicine, docetaxel and detoxifying agents for antineoplastic treatment. 
Antitijelo za uporabu prema bilo kojem od zahtjeva 1 do 14, naznačeno time da je pacijent prethodno imao terapiju s barem jednim lijekom odabranim iz skupine koja se sastoji od analoga pirimidina, platinskih spojeva, epirubicina, docetaksela i detoksikacijskih sredstava za antineoplastično liječenje.
A method of determining the responsiveness of a human cancer patient to treatment of a cancer disease with an antibody for use of any of claims 1 to 17, said method comprising the step of determining in a sample the blood level of one or more markers in the patient, wherein the one or more markers are selected from the group consisting of CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15, IFNγ, and TNFa, and a decrease in the level of at least one of the markers following administration of the antibody indicates that the patient is responsive to treatment of a cancer disease, or wherein the marker is IL-6 and an increase in the level of the marker following administration of the antibody indicates that the patient is responsive to treatment of the cancer disease. 
Postupak za određivanje reaktivnosti ljudskog pacijenta s karcinomom čovjeka na liječenje bolesti karcinoma antitijelom za uporabu prema bilo kojem od zahtjeva 1 do 17, naznačen time, da koraka određivanja razine u jednom ili više markera u uzorku u uzorku kod pacijenta, pri čemu su jedan ili više markera odabrani iz skupine koja se sastoji od CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15, IFNγ i TNFa, i smanjenja udjela razina najmanje jednog od markera nakon primjene antitijela ukazuje da pacijent reagira na liječenje bolesti raka, ili gdje je marker IL-6, a porast razine markera nakon primjene antitijela ukazuje da pacijent reagira na liječenje bolesti raka.
The zinc sheet according to claim 2, wherein the imprinted microstructures are formed by either one or both of hills and dales situated within a range of 1 to 100 μm above or below the mean surface of the sheet. 
Lim od cinka prema zahtjevu 2, naznačen time, što se otisnute mikrostrukture oblikuju pomoću bilo kojeg ili oba od brežuljaka i udolina smještenih unutar raspona od 1 do 100 µm iznad ili ispod srednje površine lima.
A decoking assembly comprising: a coke cutting tool (10) configured to receive a cutting fluid from a high pressure fluid source; and 
alat za rezanje koksa (10), konfiguriran za primanje reznog fluida iz izvora fluida pod visokim tlakom; i uređaj (200) za pomicanje navedenog alata za rezanje koksa (10) u bubnju za dekoksiranje, gdje navedeni uređaj sadrži:
The decoking assembly of claim 2, wherein at least one of said channels (260A, 260B, 260C, 260D) and corresponding ones of said belts (255) define a plurality of protruding teeth (256, 261) to promote an enhancement to said cooperative rotational movement. 
Sklop za dekoksiranje u skladu s patentnim zahtjevom 2, naznačen time što najmanje jedan od navedenih kanala (260A, 260B, 260C, 260D) i odgovarajući između navedenih remena (255) omeđuju više izbočenih zuba (256, 261) radi olakšavanja pojačanja navedenog međudjelujućeg rotacijskog gibanja.
The decoking assembly of claim 8, wherein said primary load belt (255A) and a respective channel (260A, 260B, 260C, 260D) within said pulley (260, 360) define a plurality of protruding teeth to promote an enhancement to said cooperative rotational movement. 
Sklop za dekoksiranje u skladu s patentnim zahtjevom 8, naznačen time što navedeni primarni opteretni remen (255A) i odgovarajući kanal (260A, 260B, 260C, 260D) u navedenom vitlu (260, 360) omeđuju više izbočenih zuba radi olakšavanja pojačanja navedenog međudjelujućeg rotacijskog gibanja.
The decoking assembly of claim 1, wherein at least one of said belts (255, 355) comprises a carbon fiber reinforcement. 
Sklop za dekoksiranje u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan od navedenih remena (255, 355) sadrži ojačanje ugljičnim vlaknima.
from about 10% to about 25% w/w of a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion is about 1:1 and greater than 70% of the ledipasvir is amorphous; 
Farmaceutski sastav koji sadrži: od oko 10% do oko 25% masenog udjela čvrste disperzije koja sadrži ledipasvir koji je raspršen unutar matrice polimera oblikovane od kopovidona, pri čemu je odnos masa ledipasvira prema kopovidonu u čvrstoj disperziji oko 1:1 i gdje ledipasvir ima formulu:
from about 1% to about 10% w/w of croscarmellose sodium; 
od oko 1% do oko 10% masenog udjela kroskarmeloze natrija;
from about 0.5% to about 3% w/w of colloidal silicon dioxide; and 
od oko 0.5% do oko 3% masenog udjela koloidnog silicijevog dioksida; i
from about 0.1% to about 3% w/w of magnesium stearate. 
od oko 0.1% do oko 3% masenog udjela magnezijevoga stearata.
The method of claim 6, wherein the fixed dose combination tablet is administered for about 8 weeks or less. The method of claim 6, wherein the fixed dose combination tablet is administered for about 6 weeks or less. The method of claim 6, wherein the fixed dose combination tablet is administered once daily for about 12 weeks or less and wherein the hepatitis C virus is genotype 1, 2, 3, 4, 5, or 6. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, pri čemu se farmaceutski sastav ili doza unosi jednom dnevno oko 12 tjedana ili manje, poželjno jednom dnevno oko 8 tjedana ili manje, i poželjnije jednom dnevno oko 6 tjedana ili manje, i gdje je virus hepatitisa C genotipa 1, 2, 3, 4, 5, ili 6.
The method of claim 11, wherein the hepatitis C virus is genotype 1a or 1b. 
Farmaceutski sastav za upotrebu prema zahtjevu 5, gdje je virus hepatitisa C genotipa 1a ili 1b.
a variable heavy domain comprising SEQ ID NO: 160; and 
varijabilnu tešku domenu koja sadrži SEQ ID NO: 160; i
a variable light domain comprising SEQ ID NO:165. 
varijabilna laku domenu koja sadrži SEQ ID NO: 165.
A multilayer tablet for controlled release of a magnesium salt, oxide or hydroxide, for use in the treatment of states, disorders or conditions caused by magnesium deficiency, comprising: 
Višeslojna tableta s kontroliranim oslobađanjem magnezijeve soli, oksida ili hidroksida, za upotrebu u liječenju stanja, poremećaja ili statusa uzrokovanih nedostatkom magnezija, koja sadrži:
a sustained-release layer containing (i) a polymer able to form a hydrogel matrix when it comes into contact with the fluids of the gastrointestinal tract, (ii) an organic acid able to dissociate in the gastrointestinal fluids, selected from citric acid, tartaric acid, ascorbic acid and lactic acid, and (iii) a magnesium oxide or hydroxide or a magnesium salt as defined above; 
sloj za odgođeno oslobađanje koji sadrži (i) polimer koji može tvoriti matricu hidrogela kad dođe u doticaj s tekućinama gastrointestinalnog trakta, (ii) organsku kiselinu koja može disocirati u gastrointestinalnim tekućinama, odabranu od limunske kiseline, vinske kiseline, askrobinske kiseline i mliječne kiseline, te (iii) magnezijev oksid ili hidroksid ili magnezijevu sol kao što je gore definirano; te opcionalno,
Tablet for use according to claim 1, wherein the amount of said magnesium salt, oxide or hydroxide ranges from 10 to 85% of the total weight of the tablet. 
Tableta za upotrebu prema patentnom zahtjevu 1, naznačeno time da je količina rečene magnezijeve soli, oksida ili hidroksida u rasponu od 10 do 85% ukupne mase tablete.
Tablet for use according to claim 3, wherein said disintegrating agent is present in the immediate gastric release layer in amounts ranging from 0.5% to 8%, preferably from 1% to 4%, of the total weight of the tablet. 
Tableta za upotrebu prema patentnom zahtjevu 3, naznačeno time da je prisutna količina rečenog sredstva za raspadanje u sloju za trenutačno oslobađanje u želucu u rasponu od 0.5% do 8%, preferirano od 1% do 4%, ukupne mase tablete.
Tablet for use according to claim 1, wherein said binding polymer is selected from hydroxypropylcellulose, hydroxypropylmethylcellulose and polyvinylpyrrolidone. 
Tableta za upotrebu prema patentnom zahtjevu 1, naznačeno time da je rečeni vezivni polimer odabran od hidroksipropilceluloze, hidroksipropilmetilceluloze i polivinilpirolidona.
Tablet for use according to claim 5, wherein said binding polymer is present in the immediate gastric release layer in amounts ranging from 1% to 5% of the total weight of the tablet. 
Tableta za upotrebu prema patentnom zahtjevu 5, naznačeno time da je prisutna količina rečenog vezivnog polimera u sloju za trenutačno oslobađanje u želucu u rasponu od 1% do 5% ukupne mase tablete.
Tablet for use according to claim 1, wherein said polymer which is able to form a hydrogel matrix when it comes into contact with the fluids of the gastrointestinal tract is selected from hydroxypropylmethylcellulose, hydroxypropylcellulose and hydroxyethylcellulose. 
Tableta za upotrebu prema patentnom zahtjevu 1, naznačeno time da je rečeni polimer koji može tvoriti matricu hidrogela kad dođe u doticaj s tekućinama gastrointestinalnog trakta odabran od hidroksipropilmetilceluloze, hidroksipropilceluloze te hidroksietilceluloze.
Tablet for use according to claims 7-8, containing 45 mg to 135 mg, preferably 60 mg to 115 mg, of said polymer in the sustained-release layer. 
Tableta za upotrebu prema patentnim zahtjevima 7-8, koja sadrži 45 mg do 135 mg, preferirano 60 mg do 115 mg, rečenog polimera u sloju za odgođeno oslobađanje.
Tablet for use according to claim 1, wherein said organic acid able to dissociate in the gastrointestinal fluids is present in the sustained-release layer in amounts ranging from 5 to 25%. 
Tableta za upotrebu prema patentnom zahtjevu 1, naznačeno time da je prisutna količina rečene organske kiseline koja može disocirati u gastrointestinalnim tekućinama u sloju za odgođeno oslobađanje u rasponu od 5 do 25%.
Tablet for use according to the preceding claims, further comprising, in the layers wherein they are not already present, excipients and/or additives suitable for pharmaceutical use selected from binders, lubricants, glidants, sweeteners and natural flavourings. 
Tableta za upotrebu prema prethodnim patentnim zahtjevima, koja dalje sadrži, u slojevima u kojima nisu već prisutni, ekscipijense i/ili aditive pogodne za farmaceutsku upotrebu odabrane od veziva, lubrikanata, glidanata, zaslađivača i prirodnih sredstava za poboljšavanje okusa.
Tablet for use according to claim 1, wherein said states, disorders or conditions are associated with fatigue, sense of weakness and irritability. 
Tableta za upotrebu prema patentnom zahtjevu 1, naznačeno time da su rečena stanja, poremećaji ili statusi povezani s umorom, osjećajem slabosti i razdražljivosti.
expressing a long non-coding RNA molecule involved with differentiation; triggering a disease-specific immune response. A method for treating an RNA composition comprising or consisting of in vitro-synthesized ssRNA or mRNA to generate a treated RNA composition, the method comprising: contacting the RNA composition or the in vitro-synthesized ssRNA or mRNA with a buffered aqueous solution comprising a double-stranded RNA-specific endoribonuclease III protein, magnesium cations at a concentration of about 1-4 mM and a salt providing an ionic strength equivalent to at least about 50 mM potassium acetate or potassium glutamate, and incubating under conditions such that a treated RNA composition is generated. 
Obrađeni sastav ribonukleinske kiseline (dalje u tekstu:RNA), koji sadrži in vitro sintetiziranu ssRNA ili mRNA, gdje je manje od 0,01%, poželjno manje od 0,001%, nadalje, poželjno manje od 0,0002% mase RNA u spomenutom tretiranom sastavu RNA dvolančana RNA (dsRNA) veličine veće od oko 40 duljina parova; pri čemu je navedeni obrađeni sastav ribonukleinske kiseline dobiven obradom ssRNA sintetiziranom in vitro s proteinom specifičnim za dsRNA endoribonukleaza III u puferiranoj vodenoj otopini koja sadrži katione magnezija u koncentraciji od oko 1-4 mM, te soli koja daje ionsku snagu ekvivalentnu barem oko 50 mM kalijevog acetata ili kalijevog glutamata.
encodes a transcription factor; 
iv) kodira faktor transkripcije;
ii) encodes a CD protein, meaning a protein identified in the cluster of differentiation system; 
kodira CD protein, što znači protein identificiran u grupi diferencijacijskog sustava;
iv) encodes a protein in the immunoglobulin super family; 
vii) kodira protein u super imunolobulinskoj obitelji;
vi) encodes a cell surface receptor protein; 
ix) kodira protein receptora stanične površine;
xi) encodes a reporter protein; 
xiii) kodira reporterski protein;
xix) does not encode a protein or polypeptide, but instead comprises at least one long non-coding RNA (ncRNA); 
xx) ne kodira protein ili polipeptid, već umjesto toga sadrži najmanje jednu dugu nekodirajuću RNK (ncRNA);
xxii) encodes a functional protein; 
xxii) kodira funkcionalni protein;
xxiii) encodes a protein that is present on or in a cell membrane; 
xxiii) kodira protein koji je prisutan na staničnoj membrani ili u njoj;
xxiv) encodes an immune effector protein; 
xxiv) kodira protein imunog efektora;
iii) contains at least one modified ribonucleoside, selected from the group consisting of pseudouridine, 1-methyl-pseudouridine, 5-methylcytidine, 5-methyluridine, 2'-O-methyluridine, 2-thiouridine and N6-methyladenosine in place of at least a portion of the corresponding unmodified canonical ribonucleoside, that reduces the induction or activation of an RNA sensor or innate immune response pathway in a cell; or 
iv) navedena ssRNA ili mRNA sadrži najmanje jedan modificirani ribonukleozid, izabran iz skupine koja sadrži pseudouridin, 1-metilpseudouridin, 5-metilcitidin, 5-metiluridin, 2'-O-metiluridin i 2-tiouridin umjesto najmanje dio odgovarajućeg nemodificiranog kanonskog ribonukleozida, koji smanjuje indukciju ili aktivaciju RNA senzora ili urođenog puta imunog odgovora u stanici;
repeatedly or continuously introducing into the cell an RNA composition comprising mRNA that encodes the at least one protein of interest, wherein said RNA composition has been treated with RNaseIII in a buffered aqueous solution comprising magnesium cations at a concentration of about 1-4 mM and a salt providing an ionic strength equivalent to at least about 50-300 mM potassium acetate or potassium glutamate, wherein less than 0.01% of the mass of RNA in said treated RNA composition is dsRNA of a size greater than about 40 basepairs in length, and culturing the cell under conditions wherein the cell survives, and wherein the mRNA is translated. 
Obrađeni sastav ribonukleinske kiseline (dalje u tekstu:RNA), koji sadrži in vitro sintetiziranu ssRNA ili mRNA, gdje je manje od 0,01%, poželjno manje od 0,001%, nadalje, poželjno manje od 0,0002% mase RNA u spomenutom tretiranom sastavu RNA dvolančana RNA (dsRNA) veličine veće od oko 40 duljina parova; pri čemu je navedeni obrađeni sastav ribonukleinske kiseline dobiven obradom ssRNA sintetiziranom in vitro s proteinom specifičnim za dsRNA endoribonukleaza III u puferiranoj vodenoj otopini koja sadrži katione magnezija u koncentraciji od oko 1-4 mM, te soli koja daje ionsku snagu ekvivalentnu barem oko 50 mM kalijevog acetata ili kalijevog glutamata.